DOCSLIB.ORG

EBMT-Annual-Report-2019.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

TABLE OF CONTENTS Foreword by the EBMT President 2 About the European Society for Blood and Marrow Transplantation 3 EBMT structure 4 Staff organisational chart 5 EBMT membership 6 Legal and regulatory activities 8 SCIENCE The scientific activity reports 11 Severe Aplastic Anaemia Working Party (SAAWP) 12 Autoimmune Diseases Working Party (ADWP) 14 Acute Leukaemia Working Party (ALWP) 16 Cellular Therapy & Immunobiology Working Party (CTIWP) 18 Infectious Diseases Working Party (IDWP) 20 Inborn Errors Working Party (IEWP) 22 Lymphoma Working Party (LWP) 24 Paediatric Diseases Working Party (PDWP) 26 EBMT Chronic Malignancies Working Party (CMWP) 28 Transplant Complications Working Party (TCWP) 30 EBMT Publications 2019 32 EBMT Transplant Activity Survey 2018 38 The EBMT Registry 41 EDUCATION EBMT 45th Annual Meeting 45 Awards 48 Educational events 2019 50 New EBMT e-learning platform 51 PATIENT CARE EBMT Nurses Group Activity Report 53 Highlights of the JACIE’s activities 56 Financial Report and Highlights 2019 60 EBMT’s partners 64 Foreword by the EBMT President Nicolaus Kröger EBMT President As president of our society I am very proud and honored to Patient, Family and Donor Day into the congress as well as present the EBMT activity report summarising the amazing the launch of the 1st Transplant Coordinator Day was very well achievements of our society in 2019. received and was based on our strategy to provide patients with a voice in a patient-focused society as well as including In our annual report you can follow the scientific and all health care providers involved in stem cell transplantation educational activities of our working parties and nurses’ and cellular therapies. group as well as the different committees over the last twelve months, as evidenced by many achievements including an Early in 2019, the EBMT registry received a regulatory increasing number of publications in high rank peer reviewed qualification from the European Medicine Agency (EMA) on journals and cutting-edge educational events. Together these the use of its patient registry to support novel CAR-T cell activities reflect once again this year, EBMT’s pioneering therapies which support our efforts to register all CAR-T cell role in promoting and advancing the field of stem cell and other immune effector cell treatments in our registry. transplantation and cellular therapies. pg. 2 pg. In order to collect all CAR-T cell procedures in Europe in By adhering to our EBMT educational strategy, in 2019 we our registry, we contacted national study groups, medical increased our educational activities and prioritised our efforts societies, health authorities and pharmaceutical industry to and human resources into educational events. work on a governance structure, which will provide access to CAR-T cell results to all stakeholders. In addition to the numerous educational events of the working parties in 2019, the newly established mid-size events such In addition, in January 2020, EBMT announced a new as the well-attended and successful EBMT GvHD summit collaboration with Novartis Pharmaceuticals to study in Warsaw and the international transplant course (ITC) in the long-term outcomes of patients treated with CAR-T Barcelona reflect this strategy. In January we performed therapies. together with the European Hematology Association (EHA) an extremely successful and important 1st European CAR-T Beside these achievements, we are still facing with the Cell Meeting in Paris, which with more than 600 attendees underestimated workload of data migration from ProMISe to was “sold out” after only a few weeks after its announcement. the new registry system MACRO and for this reason we were The 2nd European CAR-T Cell Meeting in Sitges in early not able to launch the new system in 2019. Nevertheless, I 2020, with more than 1,000 registrations, received similar am very optimistic that we will solve this issue very soon. attractiveness, demonstrating also our leading educational As you can see and read on the following pages, 2019 has role in cell and gene therapy. been a year of remarkable and amazing progress in many Thanks to the support of DKMS we could launch the aspects and fields and I would like to express my deep e-learning platform and in 2020 several webinars and online gratitude to all who contribute to the fabulous activities of our learning modules will be released to improve knowledge society in 2019 including the centers of EBMT in Europe and of all health care providers working in the field of stem cell around the world, who report patient outcome data to our transplantation and cellular therapies. The new EBMT registry. Handbook was launched in 2019 and has become a new Please enjoy reading the annual report and continue your standard in the field of stem cell transplantation where it commitment to EBMT in 2020. Please give us also any can be used as an optimal preparation process in order feedback and try to attend the different working party to pass the first EBMT exam, which will be launched at business meetings or educational events and contribute EBMT’s Annual Meeting in Madrid and will provide a personal actively as part of our society and by moving the field forward qualification for physicians working in the field of stem cell in order to save more life of our patients. transplantation and cellular therapy. The 45th Annual Meeting of EBMT in Frankfurt was one of most successful and record-breaking EBMT congresses Nicolaus Kröger with more than 5,600 attendees from 91 countries and up-to-date and cutting-edge presentations about stem cell transplantation and cellular therapies. The inclusion of the The EBMT is a not-for profit medical and About scientific organisation established in 1974. It is dedicated to fighting life-threatening blood cancers and diseases and improving patients’ the European lives. EBMT members–more than 5,000 physicians, Society for nurses, scientists and other healthcare professionals–participate in a unique collaborative network of peers involved in Blood and haematopoietic stem cell transplantation (HSCT) and cellular therapy research. Membership encompasses more than 550 Marrow centres from over 70 countries, that perform or are involved in HSCT. Transplantation The EBMT holds a central role in performing co-operative studies and disseminating state- of-the-art knowledge: the aim is to increase survival rates and enhance the quality of life of patients with life-threatening blood cancers and EBMT diseases. THE EBMT IS BUILT ON 3 PILLARS SCIENCE EDUCATION PATIENT CARE PATIENT EBMT STRUCTURE 14. Infectious Diseases 1 2/9 3 BOARD Jan Styczynski University Hospital, Collegium Medicum UMK 1 1. Executive Committee, President Bydgoszcz, Poland Nicolaus Kröger University Hospital Eppendorf 15. Inborn Errors Hamburg, Germany Arjan Lankester Leiden University Hospital 2. Executive Committee, Secretary Leiden, The Netherlands Rafael Duarte Hospital Universitario Puerta de Hierro 16. Lymphoma 4/12 5/13 6/11/22 Madrid, Spain Silvia Montoto St. Bartholomew’s and The Royal London 3. Executive Committee, Treasurer NHS Trust Harry Dolstra London, UK Radboud University Medical Centre Nijmegen, Netherlands 17. Paediatric Diseases Selim Corbacioglu 4. Scientific Council Chair with Children`s Hospital Regensburg Research and Sciences Portofolio Regensburg, Germany Mohamad Mohty Hospital Saint Antoine 18. Chronic Malignancies 7/19 8 10 Paris, France Ibrahim Yakoub-Agha Lille Hospital 5. Scientific Council Vice-Chair with Lille, France Research and Sciences Portofolio Christian Chabannon 19. Transplant Complications Institut Paoli Calmettes Grzegorz W. Basak Marseille, France Medical University of Warsaw Warsaw, Poland 6. Scientific Council Representative with the Registry Portofolio 14 15 John Snowden 16 Sheffield Teaching Hospitals NHS Trust COMMITTEES pg. 4 pg. Sheffield, UK 7. Scientific Council Representative with 20. Nuclear Accident the Education Portofolio Ray Powles Grzegorz W. Basak Cancer Center London Medical University of Warsaw London, UK Warsaw, Poland 21. Statistical 8. Nurse Group President Simona Iacobelli 17 18 20 John Murray Hospital Saint Antoine Christie NHS Trust Hospital Paris, France Manchester, UK 22. JACIE 9. EBMT 2020 Annual Meeting John Snowden President Sheffield Teaching Hospitals NHS Trust Rafael Duarte Sheffield, UK Hospital Universitario Puerta de Hierro Madrid, Spain 23. Donor Outcomes Nina Worel 21 23 24 Medical University of Vienna Vienna, Austria SCIENTIFIC COUNCIL - 24. Registry Per Ljungman WORKING PARTIES Karolinska University Hospital Stockholm, Sweden 10. Severe Aplastic Anaemia 25. Global Régis Peffault de Latour Norbert-Claude Gorin Hospital Saint Louis Hospital Saint Antoine 25 26 27 Paris, France Paris, France 11. Autoimmune Diseases 26. Legal & Regulatory Affairs (LRAC) John Snowden Jürgen Kuball Sheffield Teaching Hospitals NHS Trust UMC Utrecht Utrecht, Sheffield, UK Netherlands 12. Acute Leukaemia 27. Pharmacist Mohamad Mohty Tiene Bauters Hospital Saint Antoine Paediatric Clinic Prinses Elisabeth 28 Paris, France Gent, Belgium 13. Cellular Therapy & Immunobiology 28. Patient, Family and Donor Christian Chabannon Bregje Verhoeven Institut Paoli Calmettes Hematon patient organisation Marseille, France Utrecht, The Netherlands STAFF ORGANISATIONAL CHART 1. Manuela Badoglio (ADWP SC) 7. Philippe Yakonowsky (TCWP SC) 2. Hervé Finel (LWP SC) Emmanuelle Polge 3. Pascale Ambron (ALWP SC) Jessica Lemaitre (VOD Registry) (Data Office Manager Paris) 4. Arnaud Dalissier (PDWP SC) 5. Irma Khvedelidze (ALWP & LWP SC) Monica Jana (DM & assist.) 6. Mohamed Houhou (ALWP SC) William Boreland (Jr DM Pharma) 1. Paul Bosman (Senior DM & SC) 1. Anja Henseler (DM) 2. Linda Koster (CMWP SC) 2. Tirlain Sirait (CMWP Jr DM) Marco Bressers 3. Nina Knelange (IDWP SC) 3. Nienke Zinger (CMWP Jr DM) (Data Office Manager Leiden) 4. Sheree Hazelaar (IEWP SC) 4. Lotus Wendel (IDWP Jr DM) 5. Anne Lippinkhof (WPN Jr SC) 5. Annelot van Ameronger (pharma Jr DM) 6.- Jorinde Hoogenboom (CTIWPJr SC) 6. Brian Piepenbroek (SAAWP Jr DM) Marianne Mol Clinical Research 1. Myriam Labopin (Senior Paris) 1. Dirk-Jan Eikema (CM & SAAWP Leiden) Director 2. Ariane Boumendil (Senior Paris) 2. Katya Mauff (Pharma-CM & CTIWP 3.
Recommended publications
  • Euro GTP Guidance

    Euro GTP Guidance

    EURO­GTP Euro GTP Guidance European Union Project in the framework of the Public Health Program Agreement number: 2007 207 Coordinator: Transplant Services Foundation 1 List of Authors ‐ Euro GTP Project Coordinator TSF ▪ Transplant Services Foundation | Spain Project Partners BISLIFE | Netherlands BTV ▪ Banca Tessuti della Regione Veneto | Italy CBC ▪ Hornhautbank Berlin Charite Universitatsmedizin | Germany EHB ▪ European Homograft Bank | Belgium ESB ▪ Euro Skin Bank | Netherlands HBM ▪ Hornhautbank München Gemeinnutzige | Germany ISS‐CNT ▪ Istituto Superiore di Sanita Centro Nazionale Trapianti | Italy KCBTiK ▪ Krajowe Centrum Bankowania Tkanek I Komórek | Poland QAMH ▪ Queen Astrid Military Hospital | Belgium REGEA ▪ Tampere Yliopisto. University of Tampere | Finland i Table of Contents PURPOSE AND SCOPE ................................................................................................................................................1 SECTION A: GENERAL REQUIREMENTS .......................................................................................................................3 A.1. PERSONNEL ............................................................................................................................................................... 3 A.2. FACILITIES AND EQUIPMENT ..................................................................................................................................... 8 A.2.1. FACILITIES, EQUIPMENT AND MATERIALS FOR RECOVERY...............................................................................
  • Freezing of Surplus Donated Whole Eyes in the Central Eye Bank of Iran

    Freezing of Surplus Donated Whole Eyes in the Central Eye Bank of Iran

    RESEARCH Freezing of Surplus Donated Whole Eyes in the Central Eye Bank of Iran Use of Defrosted Corneas for Deep Anterior Lamellar Keratoplasty and Report of Postoperative Eye Bank Data Mozhgan Rezaei Kanavi, MD; Mohammad Ali Javadi, MD; Fatemeh Javadi; Tahereh Chamani, MS ABSTRACT especially when a shortage exists for fresh donor corneas for transplantation. PURPOSE: To describe the method of freezing and thaw- KEYWORDS: cornea, freezing, whole eyes, DALK, ing of donated whole eyes (DWEs), which were surplus to eye banks, thawing....................................... requirements in the Central Eye Bank of Iran (CEBI), and to report the 3-year results of using defrosted corneas in deep anterior lamellar keratoplasty (DALK) in keratoconic eyes. he Central Eye Bank of Iran (CEBI) is the METHODS: The method of freezing and thawing of only eye bank in Iran and is located in Tehran. surplus DWEs in the CEBI is described. Surplus DWEs Tissue requirements for corneal and scleral at the CEBI were disinfected, processed, and transferred T transplantation in Iran are supplied and preserved to the freezer (-70°C) for long-term preservation. In case 1 of a shortage of fresh and refrigerated corneas for DALK, by the CEBI. There has been an increasing trend in a frozen DWE was defrosted and distributed for trans- corneal transplantation in Iran, from 200 grafts in plantation either as a whole eye in moist chamber or as 1988 to 6,053 in 2012 (unpublished data). Keratoco- an excised corneoscleral disc in Eusol C at 2˚C to 8˚C. nus is the most common indication for penetrating Furthermore, eye bank data of the frozen DWEs as well 1 as postoperative eye bank reports of implementation of keratoplasty in Iran, accounting for 34.5% of cases.
  • Exploring Vigilance Notification for Organs

    Exploring Vigilance Notification for Organs

    NOTIFY - E xploring V igilanc E n otification for o rgans , t issu E s and c E lls NOTIFY Exploring VigilancE notification for organs, tissuEs and cElls A Global Consultation e 10,00 Organised by CNT with the co-sponsorship of WHO and the participation of the EU-funded SOHO V&S Project February 7-9, 2011 NOTIFY Exploring VigilancE notification for organs, tissuEs and cElls A Global Consultation Organised by CNT with the co-sponsorship of WHO and the participation of the EU-funded SOHO V&S Project February 7-9, 2011 Cover Bologna, piazza del Nettuno (photo © giulianax – Fotolia.com) © Testi Centro Nazionale Trapianti © 2011 EDITRICE COMPOSITORI Via Stalingrado 97/2 - 40128 Bologna Tel. 051/3540111 - Fax 051/327877 [email protected] www.editricecompositori.it ISBN 978-88-7794-758-1 Index Part A Bologna Consultation Report ............................................................................................................................................7 Part B Working Group Didactic Papers ......................................................................................................................................57 (i) The Transmission of Infections ..........................................................................................................................59 (ii) The Transmission of Malignancies ....................................................................................................................79 (iii) Adverse Outcomes Associated with Characteristics, Handling and Clinical Errors
  • GWG-Reappointment Bios

    GWG-Reappointment Bios

    Agenda Item # 12 6/22-3/11 ICOC Meeting Reappointment of Grants Working Group Scientific Members with Expiring Terms Scientific members of the Grants Working Group (GWG) are normally appointed for a period of six years. The original cohort of scientific members was appointed in May and June of 2005 and therefore their terms are now expiring. Since their original appointment, some of the original members have resigned their appointment from the GWG due to various reasons including other competing commitments. Dr. Alan Trounson and CIRM recommend the reappointment of the following members for an additional 6 year term based on their ongoing participation in CIRM reviews, their distinguished status in the stem cell field, continued interest in serving, and CIRM’s need for their review expertise. Susan Bonner-Weir, Ph.D. Dr. Bonner-Weir is Senior Investigator at the Joslin Diabetes Center and Professor of Medicine at Harvard Medical School in Boston. She received her B.A. degree from Rice University and a Ph.D. in biology from Case Western Reserve University. She then completed postdoctoral training in islet morphology at Harvard Medical School and Joslin. Research in her laboratory concerns the growth and differentiation of the insulin producing pancreatic beta cells. For over twenty-five years Dr. Bonner-Weir has focused on the endocrine pancreas (the islets of Langerhans) in three areas: 1) the architecture of the islet and its implications for function; 2) the in vivo regulation of beta-cell mass; and 3) the factors involved in islet growth and differentiation. Her focus now is how to make a reliable source of new beta-cells.
  • EBAA Medical Standards – October 2016

    EBAA Medical Standards – October 2016

    Medical Standards These Standards have the approval of the Eye Banking Committee of the American Academy of Ophthalmology October 28, 2016 Published by: EBAA th 1015 18 Street, NW, Suite 1010, Washington, DC 20036, USA www.restoresight.org ©2016. EBAA. All rights reserved. Page 1 EBAA Medical Standards – October 2016 Table of Contents A1.000 Introduction and Purpose ..............................................................................................5 A1.100 Scope ......................................................................................................................5 B1.000 Active Membership .........................................................................................................5 B1.100 Eye Bank Inspection...............................................................................................6 B1.200 Inspections by Official Agencies ...........................................................................6 C1.000 Personnel and Governance .............................................................................................6 C1.100 Director...................................................................................................................6 C1.200 Medical Director ....................................................................................................7 C1.300 Staff Performing Eye Banking Functions ..............................................................8 C1.400 Change in Governance ...........................................................................................9
  • Ethical Issues in Living-Related Corneal Tissue Transplantation

    Ethical Issues in Living-Related Corneal Tissue Transplantation

    Viewpoint Ethical issues in living-related corneal J Med Ethics: first published as 10.1136/medethics-2018-105146 on 23 May 2019. Downloaded from tissue transplantation Joséphine Behaegel, 1,2 Sorcha Ní Dhubhghaill,1,2 Heather Draper3 1Department of Ophthalmology, ABSTRact injury, typically chemical burns, chronic inflamma- Antwerp University Hospital, The cornea was the first human solid tissue to be tion and certain genetic diseases, the limbal stem Edegem, Belgium 2 transplanted successfully, and is now a common cells may be lost and the cornea becomes vascula- Faculty of Medicine and 5 6 Health Sciences, Dept of procedure in ophthalmic surgery. The grafts come from rised and opaque, leading to blindness (figure 1). Ophthalmology, Visual Optics deceased donors. Corneal therapies are now being In such cases, standard corneal transplants fail and Visual Rehabilitation, developed that rely on tissue from living-related donors. because of the inability to maintain a healthy epithe- University of Antwerp, Wilrijk, This presents new ethical challenges for ophthalmic lium. Limbal stem cell transplantation is designed to Belgium 3Division of Health Sciences, surgeons, who have hitherto been somewhat insulated address this problem by replacing the damaged or Warwick Medical School, from debates in transplantation and donation ethics. lost limbal stem cells (LSC) and restoring the ocular University of Warwick, Coventry, This paper provides the first overview of the ethical surface, which in turn increases the success rates of United Kingdom considerations generated by ocular tissue donation subsequent sight-restoring corneal transplants.7 8 from living donors and suggests how these might Limbal stem cell donations only entail the removal Correspondence to be addressed in practice.
  • AMRITA HOSPITALS AMRITA AMRITA HOSPITALS HOSPITALS Kochi * Faridabad (Delhi NCR) Kochi * Faridabad (Delhi NCR)

    AMRITA HOSPITALS AMRITA AMRITA HOSPITALS HOSPITALS Kochi * Faridabad (Delhi NCR) Kochi * Faridabad (Delhi NCR)

    AMRITA HOSPITALS HOSPITALS AMRITA AMRITA AMRITA HOSPITALS HOSPITALS Kochi * Faridabad (Delhi NCR) Kochi * Faridabad (Delhi NCR) A Comprehensive A Comprehensive Overview Overview A Comprehensive Overview AMRITA INSTITUTE OF MEDICAL SCIENCES AIMS Ponekkara P.O. Kochi, Kerala, India 682 041 Phone: (91) 484-2801234 Fax: (91) 484-2802020 email: [email protected] website: www.amritahospitals.org Copyright@2018 AMRITA HOSPITALS Kochi * Faridabad (Delhi-NCR) A COMPREHENSIVE OVERVIEW A Comprehensive Overview Copyright © 2018 by Amrita Institute of Medical Sciences All rights reserved. No portion of this book, except for brief review, may be reproduced, stored in a retrieval system, or transmitted in any form or by any means —electronic, mechanical, photocopying, recording, or otherwise without permission of the publisher. Published by: Amrita Vishwa Vidyapeetham Amrita Institute of Medical Sciences AIMS Ponekkara P.O. Kochi, Kerala 682041 India Phone: (91) 484-2801234 Fax: (91) 484-2802020 email: [email protected] website: www.amritahospitals.org June 2018 2018 ISBN 1-879410-38-9 Amrita Institute of Medical Sciences and Research Center Kochi, Kerala INDIA AMRITA HOSPITALS KOCHI * FARIDABAD (DELHI-NCR) A COMPREHENSIVE OVERVIEW 2018 Amrita Institute of Medical Sciences and Research Center Kochi, Kerala INDIA CONTENTS Mission Statement ......................................... 04 Message From The Director ......................... 05 Our Founder and Inspiration Sri Mata Amritanandamayi Devi .................. 06 Awards and Accreditations .........................
  • CIBMTR Scientific Working Committee Research Portfolio July 1, 2018

    CIBMTR Scientific Working Committee Research Portfolio July 1, 2018

    CIBMTR Scientific July 1, Working Committee 2018 Research Portfolio Milwaukee Campus Minneapolis Campus Medical College of Wisconsin National Marrow Donor Program/ 9200 W Wisconsin Ave, Suite Be The Match – 500 N 5th St C5500 Minneapolis, MN 55401-9959 USA Milwaukee, WI 53226 USA (763) 406-5800 (414) 805-0700 cibmtr.org CIBMTR Scientific Working Committee Research Portfolio: July 1, 2018 TABLE OF CONTENTS 1.0 OVERVIEW .................................................................................................................................................................. 1 1.1 Membership ........................................................................................................................................................... 2 1.2 Leadership .............................................................................................................................................................. 2 1.3 Productivity ............................................................................................................................................................ 3 1.4 How to Get Involved ............................................................................................................................................ 3 2.0 ACUTE LEUKEMIA WORKING COMMITTEE .................................................................................................. 6 2.1 Leadership .............................................................................................................................................................
  • Ethical Issues in Transnational Eye Banking

    Ethical Issues in Transnational Eye Banking

    REVIEW Ethical Issues in Transnational Eye Banking Dominique E. Martin, PhD, MBBS, BA (Hons),* Richard Kelly, MD, BBiomed,† Gary L. A. Jones, BSc (Econ),‡ Heather Machin, RN, MBA,§ and Graeme A. Pollock, PhD, MPH, BSc (Hons)¶ discussion of issues relating to tissue-derived products and Purpose: To review ethical issues that may arise in the setting of musculoskeletal tissue banking, rather than eye banking transnational eye banking activities, such as when exporting or specifically.2,5 As recognized in the recent World Health importing corneal tissue for transplantation. Organization (WHO) Initiative on MPHOs, which aims “to Methods: A principle-based normative analysis of potential common support the development of global consensus on guiding dilemmas in transnational eye banking activities was performed. ethical principles for the donation and management of [MPHOs],”6 a number of ethical concerns are common to Results: Transnational activities in eye banking, like those in other all MPHOs, including ocular tissues used in transplanta- fields involving procurement and use of medical products of human tion.1,7 Common concerns associated with transnational origin, may present a number of ethical issues for policy makers and movement of MPHOs include national self-sufficiency, donor professionals. Key ethical concerns include the potential impact of autonomy, equity in resource distribution, and care of donors export or import activities on self-sufficiency of corneal tissue supply and recipients.1 In this article, we briefly review several within exporting and importing countries; potential disclosure ethical issues that may be associated with transnational eye requirements when obtaining consent or authorization for ocular banking activities, using the example of importation and tissue donation when donations may be exported; and difficulties exportation of corneas for transplantation.
  • Spain, France and Italy Are to Exchange Organs for Donation Chains

    Spain, France and Italy Are to Exchange Organs for Donation Chains

    Translation of an article published in the Spanish newspaper ABC on 10 October 2012 O.J.D.: 201504 Date: 10/10/2012 E.G.M.: 641000 Section: SOCIETY Pages: 38, 39 ----------------------------------------------------------------------------------------------------------------- This is what happened in Spain’s first ‘crossover’ transplant [For diagram see original article] Altruistic donor The chain started with the kidney donation from a ‘good Samaritan’ going to a recipient in a couple. The wife of the first recipient donated her kidney to a sick person in a second couple. The wife of the second recipient donated her kidney to a third patient on the waiting list. On the waiting list The final recipient, selected using medical criteria, was on the waiting list to receive a kidney from a deceased donor for three years. Spain, France and Italy are to exchange organs for donation chains ► The creation of this type of ‘common area’ in southern Europe will increase the chances of finding a donor match CRISTINA GARRIDO BRUSSELS | Stronger together. Although there are many things on which we find it difficult to agree, this time the strategy was clear. Spain, France and Italy have signed the Southern Europe Transplant Alliance to promote their successful donation and transplant system – which is public, coordinated and directly answerable to the Ministries of Health, as compared to the private models of central and northern Europe – to the international bodies. ‘We (Spain, France and Italy) decided that we had to do something together because we have similar philosophies, ethical criteria and structures and we could not each go our own way given how things are in the northern countries’, explained Dr Rafael Matesanz, Director of the Spanish National Transplant Organisation, at the seminar on donations and transplants organised by the European Commission in Brussels yesterday.
  • Organ Transplant Transplants E.G

    Organ Transplant Transplants E.G

    New Layout-Dt 14-2-2009 - final.pmd 1 2/14/2009, 5:16 PM FROM THE EDITOR’S DESK / CONTENTS 2 From the Editor’s Desk Dr. Reeta J. Dalal 3 Guest Editorial Dr. Sudeep Shah 4 Cadaver Transplantation Dr. Rasika Sirsat 8 Corneal Transplant Dr. Nisheeta Agarwala & Dr. Pradyna 12 Heart Transplant Dr. Kaushal Pandey 16 Frontiers of Immunosuppression in Renal Transplant Dr. Jatin Kothari 20 Liver Transplant Dr. Sudeep Shah From the 24 Live Related Renal Transplant Dr. Alan Almeida Editor’s Desk 30 Stem Cell Transplant (SCT) Dr. Asha Kapadia Worldwide tens of 32 Lung Transplant - thousands of lives are Where does it stand today? transformed by the miracle Dr. Manoj Agni of organ donation. Tissue 36 Short History of Organ Transplant transplants e.g. skin, Dr. R. A. Bhalerao cornea, bone-marrow, 38 Hinduja News vessels are invaluable. In 40 Welcome the last half century transplant surgery has transformed from research to life-saving surgery. For every successful transplant there are Editorial Board thousands who are on the waiting list and Dr. Philip Abraham Dr. Tester Ashavaid probably die waiting to receive the graft. Organ Dr. C. Balakrishnan transplants are complicated by scarcity of organ Dr. Sudeep Shah Dr. Gauri Mankekar donors, various ethical and social issues. Editor In this issue Dr. Sudeep Shah, Liver Transplant Dr. Reeta J. Dalal Surgeon at Hinduja Hospital has put together Editor Emeritus articles from various specialities to give you an Dr. V. R. Joshi ‘Update on organ transplants’. Guest Editor Dr. Sudeep Shah Photography Pramod Tandel Dr. Reeta J.
  • First Report of the National Transplant Registry 2004 BLOOD and MARROW TRANSPLANTATION

    First Report of the National Transplant Registry 2004 BLOOD and MARROW TRANSPLANTATION

    FIRST REPORT OF THE NATIONAL TRANSPLANT REGISTRY 2004 Editors Hooi L.S. Lela Yasmin Mansor With contributions by: Alan Teh K H, Chan L L, Shamala R, Choong YY, Michael Law SH, Mohamed Ezani, David Chew SP, Ganesalingam K, Lim CB, Tan SS, Goh BL, Hamdan Leman, Suzina Sheikh August 2005 © National Transplant Registry, Malaysia ISSN 1823-5719 Published by: National Transplant Registry 2nd Floor MMA House 124, Jalan Pahang 53000 Kuala Lumpur Malaysia Tel : (603) 4045 5948 Fax : (603) 4044 0613 e-mail : [email protected] Website: http://www.mst.org.my This report is copyrighted. However it may be freely reproduced without the permission of the National Transplant Registry. Acknowledgement would be appreciated. Suggested citation is: Hooi L.S., Lela Yasmin Mansor (Eds). First Report of the National Transplant Registry Malaysia 2004. Kuala Lumpur 2005. FOREWORD We are pleased to launch the first report of the National Transplant Registry (NTR). The Registry was formed in November 2003 with the primary aim of establishing a national audit to analyse and understand the demography and outcomes in the complicated field of transplantation. This first report has been made possible by the dedication, hard work and support from the various transplant source providers and data management team. Working in close collaboration with the Clinical Research Centre the NTR has made encouraging progress since its recent formation. We would like to thank the participating centres for their cooperation. Currently the Registry collects data from all centres performing organ and tissue transplantation in this country. Heart, blood and marrow transplantation data is now reported online.